Ex Vivo Culture Resting Time Impacts Transplantation Outcomes of Genome-edited Human Hematopoietic Stem and Progenitor Cells in Xenograft Mouse Models

Overview

Journal Cytotherapy

Publisher Elsevier

Specialties Cell Biology
Pharmacology

Date 2024 Mar 20

PMID 38506770

Authors

Selami Demirci

Muhammad B N Khan

Gabriela Hinojosa

Anh Le

Alexis Leonard

Khaled Essawi

Bjorg Gudmundsdottir

Xiong Liu

Jing Zeng

Zaina Inam

Rebecca Chu

Naoya Uchida

Daisuke Araki

Evan London

Henna Butt

Stacy A Maitland

Daniel E Bauer

Scot A Wolfe

Andre Larochelle

John F Tisdale

Affiliations

Soon will be listed here.

Abstract

Ex vivo resting culture is a standard procedure following genome editing in hematopoietic stem and progenitor cells (HSPCs). However, prolonged culture may critically affect cell viability and stem cell function. We investigated whether varying durations of culture resting times impact the engraftment efficiency of human CD34+ HSPCs edited at the BCL11A enhancer, a key regulator in the expression of fetal hemoglobin. We employed electroporation to introduce CRISPR-Cas9 components for BCL11A enhancer editing and compared outcomes with nonelectroporated (NEP) and electroporated-only (EP) control groups. Post-electroporation, we monitored cell viability, death rates, and the frequency of enriched hematopoietic stem cell (HSC) fractions (CD34+CD90+CD45RA- cells) over a 48-hour period. Our findings reveal that while the NEP group showed an increase in cell numbers 24 hours post-electroporation, both EP and BCL11A-edited groups experienced significant cell loss. Although CD34+ cell frequency remained high in all groups for up to 48 hours post-electroporation, the frequency of the HSC-enriched fraction was significantly lower in the EP and edited groups compared to the NEP group. In NBSGW xenograft mouse models, both conditioned with busulfan and nonconditioned, we found that immediate transplantation post-electroporation led to enhanced engraftment without compromising editing efficiency. Human glycophorin A+ (GPA+) red blood cells (RBCs) sorted from bone marrow of all BCL11A edited mice exhibited similar levels of γ-globin expression, regardless of infusion time. Our findings underscore the critical importance of optimizing the culture duration between genome editing and transplantation. Minimizing this interval may significantly enhance engraftment success and minimize cell loss without compromising editing efficiency. These insights offer a pathway to improve the success rates of genome editing in HSPCs, particularly for conditions like sickle cell disease.

References

Sankaran V, Menne T, Xu J, Akie T, Lettre G, Van Handel B . Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008; 322(5909):1839-42. DOI: 10.1126/science.1165409. View

Cohen S, Roy J, Lachance S, Delisle J, Marinier A, Busque L . Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2019; 7(2):e134-e145. DOI: 10.1016/S2352-3026(19)30202-9. View

Foss D, Muldoon J, Nguyen D, Carr D, Sahu S, Hunsinger J . Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat Biomed Eng. 2023; 7(5):647-660. PMC: 10129304. DOI: 10.1038/s41551-023-01032-2. View

Vavassori V, Ferrari S, Beretta S, Asperti C, Albano L, Annoni A . Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood. 2023; 142(9):812-826. PMC: 10644071. DOI: 10.1182/blood.2022019333. View

Locatelli F, Merli P, Strocchio L . Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016; 23(6):515-523. DOI: 10.1097/MOH.0000000000000280. View

Esrick E, Lehmann L, Biffi A, Achebe M, Brendel C, Ciuculescu M . Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease. N Engl J Med. 2020; 384(3):205-215. PMC: 7962145. DOI: 10.1056/NEJMoa2029392. View

Ferrari S, Jacob A, Beretta S, Unali G, Albano L, Vavassori V . Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol. 2020; 38(11):1298-1308. PMC: 7610558. DOI: 10.1038/s41587-020-0551-y. View

Guo B, Huang X, Broxmeyer H . Enhancing human cord blood hematopoietic stem cell engraftment by targeting nuclear hormone receptors. Curr Opin Hematol. 2018; 25(4):245-252. PMC: 6152906. DOI: 10.1097/MOH.0000000000000429. View

Leonard A, Yapundich M, Nassehi T, Gamer J, Drysdale C, Haro-Mora J . Low-Dose Busulfan Reduces Human CD34 Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice. Mol Ther Methods Clin Dev. 2020; 15:430-437. PMC: 6909187. DOI: 10.1016/j.omtm.2019.10.017. View

10.

Sharma A, Boelens J, Cancio M, Hankins J, Bhad P, Azizy M . CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023; 389(9):820-832. PMC: 10947132. DOI: 10.1056/NEJMoa2215643. View

11.

Strocchio L, Locatelli F . Hematopoietic Stem Cell Transplantation in Thalassemia. Hematol Oncol Clin North Am. 2018; 32(2):317-328. DOI: 10.1016/j.hoc.2017.11.011. View

12.

Kavanagh P, Fasipe T, Wun T . Sickle Cell Disease: A Review. JAMA. 2022; 328(1):57-68. DOI: 10.1001/jama.2022.10233. View

13.

Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D . Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2023; 42(6):877-891. PMC: 11180610. DOI: 10.1038/s41587-023-01915-4. View

14.

Chen Y, Fang S, Ding Q, Jiang R, He J, Wang Q . ADGRG1 enriches for functional human hematopoietic stem cells following ex vivo expansion-induced mitochondrial oxidative stress. J Clin Invest. 2021; 131(20). PMC: 8516455. DOI: 10.1172/JCI148329. View

15.

Lucarelli G, Gaziev J, Isgro A, Sodani P, Paciaroni K, Alfieri C . Allogeneic cellular gene therapy in hemoglobinopathies--evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant. 2011; 47(2):227-30. DOI: 10.1038/bmt.2011.79. View

16.

Quesenberry P, Goldberg L, Dooner M . Concise reviews: A stem cell apostasy: a tale of four H words. Stem Cells. 2014; 33(1):15-20. PMC: 4270885. DOI: 10.1002/stem.1829. View

17.

Essawi K, Hakami W, Khan M, Martin R, Zeng J, Chu R . Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation. Mol Ther Methods Clin Dev. 2023; 29:483-493. PMC: 10236215. DOI: 10.1016/j.omtm.2023.04.004. View

18.

Schiroli G, Conti A, Ferrari S, Della Volpe L, Jacob A, Albano L . Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. Cell Stem Cell. 2019; 24(4):551-565.e8. PMC: 6458988. DOI: 10.1016/j.stem.2019.02.019. View

19.

Charlesworth C, Camarena J, Cromer M, Vaidyanathan S, Bak R, Carte J . Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Mol Ther Nucleic Acids. 2018; 12:89-104. PMC: 6023838. DOI: 10.1016/j.omtn.2018.04.017. View

20.

. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023; 10(8):e585-e599. PMC: 10390339. DOI: 10.1016/S2352-3026(23)00118-7. View